Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

Aditya Bardia, MD, MPH, attending physician, medical oncology, Massachusetts General Hospital; associate professor, medicine, Harvard Medical School, discusses the investigation of oral selective estrogen receptor degraders (SERDs) in patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

The EMERALD trial (NCT03778931) was the first phase 3 study to evaluate an oral SERD, elacestrant, in the ER-positive, HER2-negative population. The trial was positive, leading to the submission for the approval of elacestrant in these patients, Bardia adds.

In the endocrine sensitive population, oral SERDs have a benefit over standard endocrine therapy, leading to the investigation of oral SERDs in the adjuvant setting, Bardia continues. There are ongoing trials examining novel oral SERDs vs standard endocrine therapy as adjuvant therapy for patients with early-stage breast cancer, Bardia concludes.

Funding supported by Stemline Therapeutics. Content independently developed by OncLive